Research Square
September 23, 2022
M. Grifell, Guillem Mir, Roger Estelrich-Azubide et al.
Abstract Background Despite the proliferation of new psychoactive substances (NPS) in recent years, there are many gaps in our understanding of the phenomena. Current methodologies still fail to provide timely and scientifically reliable knowledge between controlled trials and online data reports that lack analytical confirmation of the reported substances. This study tests a new online,...
Biology
August 17, 2021
Lourdes Poyatos, Esther Papaseit, Eulàlia Olesti et al.
26 citations
Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or...
Pharmaceuticals
January 28, 2021
Esther Papaseit, Eulàlia Olesti, Clara Pérez‐mañá et al.
30 citations
Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic...
Frontiers in Pharmacology
March 18, 2020
Esther Papaseit, Marta Torrens, Mireia Ventura et al.
20 citations
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2 A), 2B (5-HT2 B), and (5-HT2 C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic...
Journal of Psychoactive Drugs
June 1, 2017
Álvaro José Palma-Conesa, Mireia Ventura, Liliana Galindo et al.
65 citations
New psychoactive tryptamines may be a public health risk since they intend to mimic the hallucinogenic effects of regulated psychoactive drugs. Few studies describe uses and clinical effects of unregulated new psychoactive tryptamines. This study aims (1) to explore the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization; (2) to...
European Psychiatry
April 1, 2017
Amira Trabsa, E. Monteagudo, D.d. Mariona et al.
2 citations
Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...
European Psychiatry
March 1, 2016
I. Ezquiaga, M. Grifell, Liliana Galindo et al.
IntroductionNovel psychoactive substances (NPS) use is progressively increasing year on year. A new group of phenethylamines sold as legal stimulants and hallucinogens is being reported increasingly since 2012. Within this group, 25I-NBOMe is an outstanding substance with powerful effects and high affinity with the serotonin 2a (5HT2a) receptor. Several toxicity cases have been reported so...